pharmacy benefit managers are key players, or should be, in alleviating patients' financial burden at the pharmacy counter

This level of concentration gives these PBMs market power over data, drug coverage, and contracting--80 percent.

The hyper-consolidation, with little to no regulatory oversight, creates inappropriate negotiating leverage that discourages competition and makes it difficult to achieve transparency, affordability, and timely access for patients.

section 36(b) of the Arms Export Control Act requires that Congress receive prior notification of certain proposed arms sales as defined by that statute. Upon such notification, the Congress has 30 calendar days during which the sale may…

section 36(b) of the Arms Export Control Act requires that Congress receive prior notification of certain proposed arms sales as defined by that statute. Upon such notification, the Congress has 30 calendar days during which the sale may…

I am extremely pleased that the Senate will be voting shortly to confirm Ambassador Richard Verma to be the Deputy Secretary of State for Management and Resources at the Department of State. This role is one of the most critical positions…

So, officially, I object. The PRESIDING OFFICER. The objection is heard. The Senator from Utah.

I am here on behalf of Senator Sanders, who was pulled away from the floor on an important matter, and he asked me to object on this matter. He gave me some documentation and some points. I don't want to burden the Senate with reading…

I ask for the yeas and nays, or whatever means yes and no. The PRESIDING OFFICER. Is there a sufficient second? There appears to be a sufficient second. The clerk will call the roll. The bill clerk called the roll.

The two animal user fee programs we are reviewing today support the timely review of both pioneer and generic drugs at the Food and Drug Administration while supporting the agency's public health mission and gold standard for safety and…

Our reauthorization of user fees should not be seen by the majority or anybody as a justification to cut FDA's budget.

As you know, I am a big supporter of what you do. And we just want to go forward.

People are really concerned, and they're not all Republicans; they're independents, middle-of-the-roaders. People love whales and dolphins, and this gets them going.

The hyper-consolidation, with little to no regulatory oversight, creates inappropriate negotiating leverage that discourages competition and makes it difficult to achieve transparency, affordability, and timely access for patients.

this vote that we are about to take today has deep personal significance for me and for many others. For me, as chairman of the Senate Foreign Relations Committee, I finally have come full circle from my vote in the House of…

Under the current structure, PBMs make more money when a drug's list price increases, while patients bear the financial burden.

it is also just fascinating, because I know the area that he represents, northern Indiana.

To have the opportunity to think about these issues with Rudy is going to be an interesting opportunity.